Financials in USD. Standardized financial statements.
A compact view of how Basel Medical Group Ltd Ordinary Shares turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue? | $11.32M | $10.05M | $9.70M | $10.66M |
| Revenue Growth? | +12.6% | +3.6% | -9.0% | 0.0% |
| Cost of Revenue? | $2.53M | $2.25M | $2.34M | $2.18M |
| Gross Profit? | $8.79M | $7.80M | $7.36M | $8.48M |
| Gross Margin? | +77.7% | +77.6% | +75.9% | +79.6% |
| Operating Expenses? | $10.98M | $5.61M | $5.36M | $6.01M |
| Operating Income? | -$2.18M | $2.20M | $2.00M | $2.47M |
| EBITDA? | -$11.12M | $3.11M | $2.93M | $3.28M |
| Income Before Tax | -$12.51M | $2.40M | $2.13M | $2.39M |
| Income Tax Expense | -$417,393 | $331,761 | $348,280 | $408,480 |
| Net Income? | -$12.09M | $2.07M | $1.78M | $1.98M |
| EPS? | $0.00 | $0.11 | $0.10 | $0.11 |
| Diluted EPS? | $0.00 | $0.11 | $0.10 | $0.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality